[Combined pegylated liposomal @entity632 and @entity3003 in the treatment of recurrent XXXX ].

@entity632 @entity1 @entity43 @entity137 @entity3136 @entity6066 @entity1353 @entity3003 @entity3906 @entity1311 @entity786 @entity1370 @entity56 @entity8566 @entity1431 @entity902
OBJECTIVE: To evaluate the efficacy and @entity137 of combined pegylated liposomal @entity632 (PLD) and @entity3003 in the treatment of @entity1 with recurrent @entity43 . METHODS: We retrospectively reviewed 67 @entity1 with recurrent @entity43 or primary @entity3906 (8 cases) who were treated with combined @entity6066 and @entity3003 . The response rate, survival and @entity137 were evaluated. The mean age for 67 @entity1 was 52.1 (39 - 76) years. All of them received cytoreductive surgery followed by @entity902 -based chemotherapy either with @entity1311 or @entity786 and @entity632 after diagnosis. Combined PLD and @entity3003 was used as first or second-line treatment or even after multiple lines of treatment after disease recurred. @entity1 were treated with PLD at 35 - 40 mg/m(2) combined with @entity3003 at an area under curve (AUC) of 5 once every 4 weeks. RESULTS: Forty-nine @entity1 were evaluable for response. Twenty-three (47%) @entity1 had a complete response, 13 (27%) had a partial response, 3 (6%) had stable disease and 10 (20%) had progressive disease. The estimated median progression-free survival (PFS) was 8 months. The 1-year and 2-year survival rates were 73% and 55%, respectively. All of the 67 @entity1 were evaluated for @entity137 . The treatment was terminated in 2 @entity1 due to @entity56 -like infusion reaction. Four @entity1 who had acute infusion reaction with @entity1353 and tightness of chest did not terminate the treatment because no such reaction occurred when restarted the infusion. There were 2 @entity1 with G(2) and 3 @entity1 with G(3) @entity8566 , 2 @entity1 had G(4) @entity3136 , and 8 @entity1 had G(3) @entity1431 . No G(4) @entity1431 or @entity1370 occurred. CONCLUSION: The combination of PLD and @entity3003 is an active and well-tolerated regimen in the treatment of @entity1 with recurrent @entity43 .
